Cachexia commonly occurs at the terminal stage of cancer and has largely unclear molecular mechanisms. A recent study published in Nature Medicine, entitled "Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia," reveals that cachectic cancer cells can secrete multiple cytokines that induce excessive fatty acid oxidation, which is responsible for muscle loss in cancer cachex...

BACKGROUND We previously reported the role of IL-6 in a murine model of cancer cachexia and currently documented a patient in whom tocilizumab, anti-IL-6 receptor antibody, dramatically improved cachexia induced by IL-6 over-expressing lung cancer. Despite this potential to alleviate cancer cachexia, tocilizumab has not been approved for this clinical use. Therefore, preceding our planned clini...

Anorexia-cachexia is a progressive wasting condition that commonly affects people in the advanced stages of diseases such as cancer and acquired immune deficiency syndrome (AIDS). It is described by loss of appetite (anorexia) and loss of weight (cachexia).The word “anorexia” comes from the Greek word orexis (meaning “appetite”), literally translating to “without appetite”. The word “cachexia” ...

Background: Rheumatic Heart Disease (RHD) is still a significant cause of cardiovascular morbidity and death in developing countries like Indonesia. However, despite being one the most preventable chronic diseases, RHD receives less attention, especially Southeast Asia. PJR that not treated immediately can develop into heart failure. When failure has entered stage congestive failure, there acti...

Cancer cachexia remains a leading cause of morbidity and mortality worldwide, despite extensive research and clinical trials. The prominent clinical feature of cancer cachexia is the continuous loss of skeletal muscle that cannot be fully reversed by conventional nutritional support, and that leads to progressive functional impairment. The mechanism underlying muscle loss in patients with cache...

PURPOSE Cancer cachexia is a multifactorial syndrome characterized by progressive loss of weight and muscle atrophy. Using metabolomics, we investigated serum markers and their intra-day variation in advanced pancreatic cancer patients with cachexia. METHODS Patients were enrolled in two groups: those with or without cachexia. Blood samples collected at 6:30 AM, 11:30 AM, 4:30 PM, and 9:30 PM...

To examine the effects of aliskiren, a small-molecule renin inhibitor, on cancer cachexia and to explore the underlying mechanisms. A cancer cachexia model was established by subcutaneously injecting C26 mouse colon carcinoma cells into isogenic BALB/c mice. Aliskiren was administered intragastrically [10 mg/kg body weight (BW)] on day 5 (as a preventive strategy, AP group) or on day 12 (as a t...

Cancer-related symptoms such cachexia and pain are subjects of a proliferation of assessment tools, diagnostic criteria, and systems for staging, which are notably disparate, and lack agreement on the variables to be measured. Teams of experts have worked diligently to develop consensus definitions of the terms cachexia and cancer cachexia, and these efforts provide the basis to develop agreeme...

Cachexia is a syndrome associated with many chronic diseases and is an independent risk factor for mortality. Yet it is only in these last years that cachexia has received increasing attention, as the recently instituted international congress on this topic indicates. Here we review some of the most noteworthy contributions presented at the 4th Cachexia Conference in December 2007. Of particula...

BACKGROUND An appropriate plasma concentration of fentanyl is the key to achieving good pain control in cancer patients. Cachexia, a multifactorial syndrome, is known to affect drug-metabolizing enzymes. However, the fentanyl concentrations in the blood of patients with cachexia have not been analyzed. The aim of this study was to evaluate the influence of cancer cachexia on dose-adjusted plasm...